- Case report
- Open Access
Biclonal myelodysplastic syndrome involving six chromosomes and monoallelic loss of RB1 - A rare case
© Al-Achkar et al; licensee BioMed Central Ltd. 2011
Received: 15 June 2011
Accepted: 18 August 2011
Published: 18 August 2011
Myelodysplastic syndrome (MDS) represents a group of clonal hematological disorders characterized by progressive cytopenia, and reflects to defects in erythroid, myeloid and megakaryocytic maturation. MDS is more frequently observed in older aged patients with cytogenetic abnormalities like monosomy of chromosome(s) 5 and/or 7. In 50% of de novo MDS cases, chromosomal aberrations are found and rearrangements involving the retinoblastoma (RB1) gene in 13q14 are found.
Here, we are presenting a case report of a rare biclonal MDS with a karyotype of 45, XY,-4, der(6)t(4;6)(p15.1;p21.3), der(8)t(4;8)(q31.2;q22), t(13;16)(q21.3;p11.2)/45, XY, der(7)t(7;13)(p22.2~22.3;q21.3),-13 . The patient was diagnosed according to WHO classification as refractory anemia with excess of blasts (RAEB-II).
Immunophenotyping was positive for CD11b, CD11c, CD10, CD13, CD15, CD16 and CD33.
We report, a novel and cytogenetically rare case of a biclonal MDS with complex chromosomal aberrations and deletion of RB1-gene in both clones. These findings are associated with a poor prognosis as the patient died 3 months after diagnosis.
Myelodysplastic syndrome (MDS) refers to a group of clonal acquired diseases characterized by trilineage defects in erythrocytic, granulocytic, and megakaryocytic lineages of hematopoiesis. Although considerable as a clonal malignancy of its own, MDS is sometimes classified as a premalignant condition, which progresses to acute myeloid leukemia (AML) regularly . Overall, MDS affects approximately 1 in 500 persons over 60 years of age, making it the most common hematologic malignancy in this age group .
Cytogenetic abnormalities are found in ~50% of the patients with de novo MDS and the most commonly involved chromosomal changes observed are monosomy 5 and/or 7, trisomy 8 and/or partial deletion in 5q, 7q, 9q and 20q [2, 3]. Unbalanced translocations are also frequently found, and they are usually detected as a part of complex karyotypes, associated with loss of chromosomal material, and related to disease progression .
Deletions or translocations involving chromosomal band 13q14, the locus of the retinoblastoma (RB1) gene, are observed in a variety of hematological malignancies including myelofibrosis (MF), MDS, AML, chronic myelogenous leukemia (CML) and chronic lymphocytic leukemia (CLL) . Recently, it has been shown that deletions of 13q14 are detected at a high frequency (more than 40%) in cases of CLL and multiple myeloma (MM) by fluorescence in situ hybridization (FISH) analyses .
We are presenting a new case of a biclonal MDS case with yet unreported translocation events involving six different chromosomes and a monoallelic loss of RB1 in both clones. In this case, multicolor banding (MCB) technique was found very useful for characterizing the breakpoints involved in the chromosomal rearrangements in this case.
In June 2009, a 60 year old male patient was referred with anemia, thrombocytopenia, loss of weight and fever. His white blood cell count was 7 × 109/l, with 64.5% neutrophils, 24.6% lymphocytes, 4.2% monocytes, 1% eosinophiles, 1% basophils and 4.6% blast. Bone marrow was hypercellular with 19% blast cells. Dysplastic changes in bone marrow included cytoplasmic hypogranulation of neutrophils, erythroblasts and micromegakaryocytes. The red blood cell count was 3.38 × 106/cmm with 8.3 g/dl hemoglobin level along with platelet count of 49 × 109/l, and LDH value of 571 U/l. Physical examination of the patient showed splenomegaly. The patient was treated with Zyloric (300 mg as a daily dose) and Hydroxyurea (500 mg as a daily dose) for 1 month and later continued on Hydroxyurea (500 mg as a daily dose) for 3 month. The patient died 3 months after diagnosis.
Immunophenotyping of peripheral blood characterized the neutrophiles which showed abnormal side scatter pattern, as well as abnormal intensity staining patterns for CD11b(63%), CD11c(59.3%), CD10(17.4%), CD13(44%), CD15(59.3%), CD16(46%) and CD33(20.4%). The majority of monocytes were HLADr+ (4.2%). Lymphocyte subsets percentages were low. The patient was diagnosed as having common MDS, refractory anemia with excess of blasts (RAEB) in the French-American-British (FAB) classification, or RAEB-II in the World Health Organization (WHO) classification .
We described a biclonal MDS case with cytogenetic rearrangements involving six different chromosomes together with a monoallelic loss of the RB1 gene in both clones.
The Cancer Genome Anatomy Project databases (http://cgap.nci.nih.gov/Chromosomes/AbnCytSearchForm) and atlas of genetics and cytogenetics in oncology and hematology (http://atlasgeneticsoncology.org/) showed not a single case of MDS with a der(6)t(4;6)(p15.1;p21.3), a der(7)t(7;13)(p22.2~22.3;q21.3), a der(8)t(4;8)(q31.2;q22), or a t(13;16)(q21.3;p11.2). Contrarily the involvement of RB1 gene in MDS is known and appears to be a rare event . The RB1 protein acts as a cell cycle regulator which blocks the transition of normal cells from G0/G1 into S phase of the cycle. Mice with homozygous disruption of the RB1 alleles resulted in an overall normal development but had lethal anemia, suggesting a critical role of the RB1 gene in erythropoiesis . In the present case, anemia and thrombocytopenia were predominantly observed during the clinical course, while white blood cells count was relatively preserved. This impaired erythropoiesis might be related to monoallelic loss of the RB1 gene .
Besides imbalances of chromosomes 13, the observed rearrangements lead to a partial monosomy 4p15.1 to 4q31.2 in the slightly larger of both clones. In accordance with the international prognostic scoring system (IPSS) classification of chromosomes 4 and 13 loss in a RAEB-II stage patient supports an intermediate-2 prognosis group and/or poor prognosis group [6, 7].
The decreased heterogeneous expression of those antigens was consistent with myelodysplastic disease in transition.
Concerning the additional observed acquired imbalances, up to present somehow similar minor terminal deletions of 6p21.3 in malignant hematological disorders was observed, and an involvement of the breakpoint 8q22 in an oncogene induced solid tumor [8, 9]. Deletions of 7p confer an inferior outcome in children with ALL, regardless of the presence of other poor prognostic features. Monosomy 7 is also associated with inferior event-free survival (EFS) in children with ALL . 13q21.3 region was involved in CLL cases and 16p11.2 region was found in classical Hodgkin lymphoma but to our knowledge our breakpoints have not been reported in MDS, yet [11, 12].
According to a recent study, the LDH level was nearly as powerful as a prognostic parameter as karyotyping and an elevated LDH was associated with poor prognosis in MDS . The LDH level for the presented patient was 571 U/l, which compared to the normal value (up to 480 U/l) is enhanced. Thus, also the LDH level as well as cytogenetics supported an adverse prognosis, which unfortunately was confirmed by the clinical outcome.
In conclusion, here we reported a novel translocation involving six chromosomes distributed in two clones and monoallelic loss of RB1 in both clones. Our finding and according to WHO classification, IPSS and LDH is considered to a poor prognostic factor in MDS patients, as no response was observed after the application of chemotherapy.
Materials and methods
Chromosome analysis using GTG-banding was performed according to standard procedures . Twenty metaphases derived from unstimulated bone marrow of the patient were analyzed. Karyotypes were described according to the International System for Human Cytogenetic Nomenclature .
Fluorescence in situ hybridization (FISH) using whole chromosome painting (WCP) probe for chromosomes 4, 6, 7, 13 and 16 (MetaSystems/Germany) and subtelomeric probes for 7pter and 7qter (Abbott Molecular/Vysis, USA) were applied according to manufacturer's instructions together with a chromosome enumeration probe (CEP) for chromosome 8 and specific probe for RB1 (LSI 13 (RB1) Abbott Molecular/Vysis, USA) . Multicolor banding probe (MCB) sets based on microdissection derived region-specific libraries for chromosome 4, 7, 13 and 16 were applied as previously described . Twenty metaphase spreads were analyzed, each using a fluorescence microscope (AxioImager.Z1 mot, Zeiss) equipped with appropriate filter sets. Image capturing and processing were carried out using an Isis mFISH imaging system (MetaSystems, Altlussheim, Germany).
Immunophenotyping of leukemic blasts was done using general panel of fluorescent antibodies against the following antigens typical for different cell lineages and cell types: CD1a, CD2, CD3, CD4, CD5, CD8, CD10, CD11b, CD11c, CD13, CD14, CD15, CD16, CD19, CD20, CD22, CD23, CD32, CD33, CD34, CD38, CD41a, CD45, CD56, CD57, CD64, CD103, CD117, CD123, CD209, CD235a and CD243; In addition to antibodies to Kappa and Lambda light Chains, sIgD, sIgM, and HLADr. All antibodies were product from BD Biosciences. Four-color immunophenotyping on peripheral blood specimen was performed. Samples stained and analyzed on a BD FACSCalibur™ flow cytometer according to BD Biosciences manuals and products insert sheets. Autofluorescence, viability, and isotype controls were included. Flow cytometric data acquisition and analysis conducted by BD Cellquest™ Pro software.
Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
We thank Prof. I. Othman, the Director General of Atomic Energy Commission of SYRIA (AECS) and Dr. N. Mirali, Head of Molecular Biology and Biotechnology Department for their support. This work was supported by the AECS, in parts by the Stefan-Morsch-Stiftung and the DAAD (D/07/09624).
- Look AT: Molecular Pathogenesis of MDS. Hematology Am Soc Hematol Educ Program 2005, 156–160.Google Scholar
- Haase D, Steidl C, Schanz J, Schabla R, Pfeilstöcker M, Nösslinger T, Hildebrandt B, Kuendgen A, Lübbert M, Kunzmann B, Giagounidis A, Aul C, Trumper L, Krieger O, Fonatsch C, Valent P, Stauder R, Germing U: Correlation of cytogenetic fi ndings with morphology, clinical course and prognosis in 2124 patients with MDS. Blood 2005., 106: 232A,787Google Scholar
- Vundinti BR, Kerketta L, Jijina F, Ghosh K: Cytogenetic study of myelodysplastic syndrome from India. Indian J Med Res 2009, 130: 155–159.PubMedGoogle Scholar
- Yamamoto K, Ito M, Minagawa K, Urahama N, Sada A, Okamura A, Matsui T: A der(13)t(7;13)(p13;q14) with monoallelic loss of RB1 and D13S319 in myelodysplastic syndrome. Cancer Genet Cytogenet 2005, 162: 160–165. 10.1016/j.cancergencyto.2005.03.020PubMedView ArticleGoogle Scholar
- Invernizzi R, Filocco A: Myelodysplastic syndrome: classification and prognostic systems. Oncol Rev 2010, 4: 25–33. 10.1007/s12156-009-0033-4View ArticleGoogle Scholar
- Mitelman F, Johansson B, Mertens F, (Eds.): Mitelman Database of Chromosome Aberrations in Cancer. 2009. [http://cgap.nci.nih.gov/Chromosomes/Mitelman"]
- Fenaux P: Chromosome and molecular abnormalities in myelodysplastic syndromes. Int J Hematol 2001, 73: 429–437. 10.1007/BF02994004PubMedView ArticleGoogle Scholar
- Chen Z, Issa B, Brothman LJ, Hendricksen M, Button D, Brothman AR: Nonrandom rearrangements of 6p in malignant hematological disorders. Cancer Genet Cytogenet 2000, 121: 22–25. 10.1016/S0165-4608(00)00222-3PubMedView ArticleGoogle Scholar
- Kao C, Wu SQ, DeVries S, Reznikoff WS, Waldman FM, Reznikoff CA: Carcinogen-induced amplification of SV40 DNA inserted at 9q12–21.1 associated with chromosome breakage, deletions, and translocations in human uroepithelial cell transformation in vitro. Genes Chromosomes Cancer 1993, 8: 155–166. 10.1002/gcc.2870080304PubMedView ArticleGoogle Scholar
- Heerema NA, Nachman JB, Sather HN, La MK, Hutchinson R, Lange BJ, Bostrom B, Steinherz PG, Gaynon PS, Uckun FM: Deletion of 7p or monosomy 7 in pediatric acute lymphoblastic leukemia is an adverse prognostic factor: a report from the Children's Cancer Group. Leukemia 2004, 18: 939–947. 10.1038/sj.leu.2403327PubMedView ArticleGoogle Scholar
- David Ng, Ousmane Toure, Ming-Hui Wei, Arthur DianeC, Fatima Abbasi, Laura Fontaine, Marti GeraldE, Fraumeni JosephF Jr, Goldin LynnR, Neil Caporaso, Toro JorgeR: Identification of a novel chromosome region, 13q21.33-q22.2, for susceptibility genes in familial chronic lymphocytic leukemia. Blood 2007, 109: 916–925.Google Scholar
- Chui DT, Hammond D, Baird M, Shield L, Jackson R, Jarrett RF: Classical Hodgkin lymphoma is associated with frequent gains of 17q. Genes Chromosomes Cancer 2003, 38: 126–136. 10.1002/gcc.10266PubMedView ArticleGoogle Scholar
- Germing U, Hildebrandt B, Pfeilstöcker M, Nösslinger T, Valent P, Fonatsch C, Lübbert M, Haase D, Steidl C, Krieger O, Stauder R, Giagounidis AA, Strupp C, Kündgen A, Mueller T, Haas R, Gattermann N, Aul C: Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukemia 2005, 19: 2223–2231. 10.1038/sj.leu.2403963PubMedView ArticleGoogle Scholar
- AL-achkar W, Wafa A Nweder MS: A complex translocation t(5;9;22) in Philadelphia cells involving the short arm of chromosome 5 in a case of chronic myelogenous leukemia. Journal of Experimental and Clinical Cancer Research 2007, 26: 411–415.PubMedGoogle Scholar
- Shaffer L, Slovak M, Cambell L, (eds): ISCN (2009): An International System for Human Cytogenetic Nomenclature. 2009.Google Scholar
- Liehr T, Heller A, Starke H, Rubtsov N, Trifonov V, Mrasek K, Weise A, Kuechler A, Claussen U: Microdissection based high resolution multicolor banding for all 24 human chromosomes. Int J Mol Med 2002, 9: 335–339.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.